OmniSeq and LabCorp Extend Exclusive Distribution Pact and Complete Follow-On Investment Agreement
23 avr. 2019 08h00 HE
|
OmniSeq
BUFFALO, N.Y., April 23, 2019 (GLOBE NEWSWIRE) -- OmniSeq®, a CAP-accredited, molecular diagnostics spin-out of Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE: LH), a leading global...
OmniSeq, Inc. to Participate in the NCI-MATCH Clinical Trial
31 juil. 2018 16h05 HE
|
OmniSeq
BUFFALO, N.Y., July 31, 2018 (GLOBE NEWSWIRE) -- OmniSeq, Inc.® a leading innovator in molecular science, today announced it is participating as a CLIA-certified/accredited laboratory for the...
OmniSeq and LabCorp Launch OmniSeq Advance℠ Assay
01 juin 2018 16h11 HE
|
OmniSeq
CHICAGO, June 01, 2018 (GLOBE NEWSWIRE) -- ASCO – OmniSeq®, a CAP-accredited, molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, and LabCorp® (NYSE:LH), a leading...
Hitachi High-Tech Participates in OmniSeq Series B and Secures Japanese Distribution Rights
12 avr. 2018 09h00 HE
|
OmniSeq
BUFFALO, N.Y., April 12, 2018 (GLOBE NEWSWIRE) -- OmniSeq®, a molecular diagnostics subsidiary of the Roswell Park Comprehensive Cancer Center, announced today Hitachi High-Technologies Corporation...
OmniSeq and LabCorp Sign Exclusive Distribution Agreement and Series B Funding Commitment
21 août 2017 08h01 HE
|
OmniSeq
BUFFALO, N.Y., Aug. 21, 2017 (GLOBE NEWSWIRE) -- OmniSeq, Inc., a molecular diagnostics subsidiary of the Roswell Park Cancer Institute, announced today that it has entered into an exclusive...
Rand Partners With Innovate NY Fund to Invest in Personalized Cancer Medicine Business, Empire Genomics, LLC
01 juil. 2014 17h04 HE
|
Rand Capital Corporation
BUFFALO, NY--(Marketwired - Jul 1, 2014) - Rand Capital Corporation (www.randcapital.com) (NASDAQ: RAND) a Buffalo, New York based Business Development Company (BDC) and Small Business Investment...